Quick Answer
ENDONOVO THERAPEUTICS, INC. reported Stockholders Equity of -$32.18 million for the year ending 2022.
- ENDONOVO THERAPEUTICS, INC. showed a decrease of -104.0% in Stockholders Equity from 2021 to 2022.
- This data is from ENDONOVO THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on April 17, 2023.
- XBRL data for this metric is available from 2009 to 2022 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $0.00 | Q4 2011: -$426.0 thousand | Q1 2012: -$718.7 thousand | Q2 2012: -$1.12 million | Q3 2012: -$1.43 million | Q4 2012: -$1.88 million | Q3 2013: -$3.46 million | Q2 2015: -$5.40 million | Q3 2015: -$5.93 million | Q2 2016: -$7.25 million | Q3 2016: -$8.52 million | Q1 2017: -$13.07 million | Q2 2017: -$9.15 million | Q3 2017: -$13.18 million | Q1 2018: -$8.62 million | Q2 2018: -$9.12 million | Q3 2018: -$14.08 million | Q1 2019: -$11.62 million | Q2 2019: -$16.25 million | Q3 2019: -$16.57 million | Q1 2020: -$11.14 million | Q2 2020: -$12.18 million | Q3 2020: -$12.76 million | Q1 2021: -$15.97 million | Q2 2021: -$16.98 million | Q3 2021: -$18.22 million | Q4 2021: -$15.77 million | Q1 2022: -$18.04 million | Q2 2022: -$19.16 million | Q3 2022: -$19.61 million | Q4 2022: -$32.18 million | Q1 2023: -$24.37 million | Q2 2023: -$22.41 million | Q3 2023: -$22.96 million.
- Over the full 13 years of available data (2009 to 2022), ENDONOVO THERAPEUTICS, INC.'s Stockholders Equity has declined by 13,767.6%.
- Historical annual values: Fiscal year 2022: -$32.18 million | Fiscal year 2021: -$15.77 million | Fiscal year 2020: -$14.37 million | Fiscal year 2019: -$20.50 million | Fiscal year 2018: -$11.39 million | Fiscal year 2017: -$9.55 million | Fiscal year 2016: -$8.56 million | Fiscal year 2015: -$9.28 million | Fiscal year 2014: -$4.69 million | Fiscal year 2013: -$4.13 million | Fiscal year 2011: $72.0 thousand | Fiscal year 2010: $166.1 thousand | Fiscal year 2009: $235.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: